{
    "organizations": [],
    "uuid": "fbb6f086c553bd64e41a48bc5b0ec4db5ff196f6",
    "author": "",
    "url": "https://www.reuters.com/article/brief-beigene-presents-clinical-data-on/brief-beigene-presents-clinical-data-on-pamiparib-in-chinese-patients-with-ovarian-cancers-at-the-american-association-for-cancer-research-annual-meeting-idUSFWN1RT0N6",
    "ord_in_thread": 0,
    "title": "BRIEF-Beigene Presents Clinical Data On Pamiparib In Chinese Patients With Ovarian Cancers At The American Association For Cancer Research Annual Meeting",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Market News April 16, 2018 / 1:31 PM / Updated 6 minutes ago BRIEF-Beigene Presents Clinical Data On Pamiparib In Chinese Patients With Ovarian Cancers At The American Association For Cancer Research Annual Meeting Reuters Staff 1 Min Read \nApril 16 (Reuters) - Beigene Ltd: \n* BEIGENE PRESENTS CLINICAL DATA ON PAMIPARIB IN CHINESE PATIENTS WITH OVARIAN CANCERS OR TRIPLE-NEGATIVE BREAST CANCER AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING \n* BEIGENE LTD - PAMIPARIB WAS SHOWN TO BE GENERALLY WELL TOLERATED \n* BEIGENE LTD - LOOK FORWARD TO ADVANCING PAMIPARIBâ€™S DEVELOPMENT IN CHINA AS WELL AS INITIATING A GLOBAL PHASE 3 TRIAL \n* BEIGENE - IN PATIENTS WITH OVARIAN, BREAST CANCER, PRELIM RESULTS SUPPORT RECOMMENDED PAMIPARIB DOSING REGIMEN, DEMONSTRATED ANTITUMOR ACTIVITY \n* BEIGENE-SAW NO DOSE-LIMITING TOXICITIES, FOUND PAMIPARIB TO BE GENERALLY WELL TOLERATED AMONG THE PRE-TREATED PATIENTS WITH OVARIAN, BREAST CANCERS Source text for Eikon: Further company coverage:",
    "published": "2018-04-16T16:29:00.000+03:00",
    "crawled": "2018-04-16T16:43:39.022+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "present",
        "clinical",
        "data",
        "pamiparib",
        "chinese",
        "patient",
        "ovarian",
        "cancer",
        "american",
        "association",
        "cancer",
        "research",
        "annual",
        "meeting",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "beigene",
        "ltd",
        "beigene",
        "present",
        "clinical",
        "data",
        "pamiparib",
        "chinese",
        "patient",
        "ovarian",
        "cancer",
        "breast",
        "cancer",
        "american",
        "association",
        "cancer",
        "research",
        "annual",
        "meeting",
        "beigene",
        "ltd",
        "pamiparib",
        "shown",
        "generally",
        "well",
        "tolerated",
        "beigene",
        "ltd",
        "look",
        "forward",
        "advancing",
        "pamiparib",
        "development",
        "china",
        "well",
        "initiating",
        "global",
        "phase",
        "trial",
        "beigene",
        "patient",
        "ovarian",
        "breast",
        "cancer",
        "prelim",
        "result",
        "support",
        "recommended",
        "pamiparib",
        "dosing",
        "regimen",
        "demonstrated",
        "antitumor",
        "activity",
        "toxicity",
        "found",
        "pamiparib",
        "generally",
        "well",
        "tolerated",
        "among",
        "patient",
        "ovarian",
        "breast",
        "cancer",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}